The Effect of Metformin versus Orlistat on Cardiovascular and Metabolic profile in Obese Children: A Randomized Control Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202606518409008

Enrollment

Registered

2026-06-18

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paediatrics

Interventions

metformin group

orlistat

placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children aged 12–17 years whose body mass index (BMI) is = 95th percentile for age and sex for more than 6 months

Exclusion criteria

Exclusion criteria: • Secondary causes of obesity (genetic or endocrine) • Type 1 or type 2 diabetes mellitus • Chronic systemic diseases such as renal, hepatic, or cardiovascular disease. • Use of medications that affect the cardiovascular, weight, or metabolism within the last 3 months. • Known hypersensitivity to metformin or orlistat

Design outcomes

Primary

Measure	Time frame
Changes in BMI	—

Secondary

Measure	Time frame
-Changes in cardiovascular parameters such as BP, Echocardiographic parameters, carotid intima media thickness, and flow dilatiotion. Changes in metabolic parameters such as FBG, FBI, HOMA-IR, and lipid profile	—

Countries

Egypt

Contacts

Public ContactHassnaa Elkady

resident at Tanta university hospital

mohamedkashlan@yahoo.com+201222337746

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Jun 29, 2026